My ePortfolio Register   
 

Abstract | Full HTML Article | PDF ecancer 10 684 / DOI: 10.3332/ecancer.2016.684

Special Issue

Next-generation sequencing in NSCLC and melanoma patients: a cost and budget impact analysis

Next-generation sequencing (NGS) has reached the molecular diagnostic laboratories. Although the NGS technology aims to improve the effectiveness of therapies by selecting the most promising therapy, concerns are that NGS testing is expensive and that the ‘benefits’ are not yet in relation to these costs. In this study, we give an estimation of the costs and an institutional and national budget impact of various types of NGS tests in non-small-cell lung cancer (NSCLC) and melanoma patients within the Netherlands. First, an activity-based costing (ABC) analysis has been conducted on the costs of two examples of NGS panels (small- and medium-targeted gene panel (TGP)) based on data of the Netherlands Cancer Institute (NKI). Second, we performed a budget impact analysis (BIA) to estimate the current (2015) and future (2020) budget impact of NGS on molecular diagnostics for NSCLC and melanoma patients in the Netherlands. Literature, expert opinions, and a data set of patients within the NKI (n = 172) have been included in the BIA. Based on our analysis, we expect that the NGS cost concerns will be limited. In the current situation, NGS can indeed result in higher costs, which is mainly related to required additional tests besides the small TGP. However, in the future, we expect that the use of whole-genome sequencing (WGS) will increase, for which it is expected that additional tests can by (partly) avoided. Although the current clinical benefits are expected to be limited, the research potentials of NGS are already an important advantage.

Keywords: Next-generation sequencing, test costs, budget impact, melanoma, NSCLC, personalised medicine, targeted therapy

Loading Article Metrics ... Please wait

Related articles

Conference Report: Highlights from the first ecancer–Liga Colombiana contra el Cancer conference, 17–18 November 2016, Bogota, Colombia

Abstract | Full Article | PDF | Spanish Published: 28 Mar 2017 / DOI: 10.3332/ecancer.2017.730

Conference Report: Highlights from the ecancer Future Horizons in Lung Cancer conference, 1–2 September 2016: Focusing on the future of treatment for NSCLC and SCLC

Abstract | Full Article | PDF Published: 23 Mar 2017 / DOI: 10.3332/ecancer.2017.729

Conference Report: Highlights from the 36th European Society of Surgical Oncology Congress (ESSO 36), 14–16 September 2016, Kracow, Poland: optimising European cancer surgery

Abstract | Full Article | PDF Published: 23 Mar 2017 / DOI: 10.3332/ecancer.2017.728

Conference Report: Highlights from the 58th meeting of the American Society of Haematology, 1–6 December 2016, San Diego, USA

Abstract | Full Article | PDF Published: 09 Mar 2017 / DOI: 10.3332/ecancer.2017.725

Review: Dual role of inflammatory mediators in cancer

Abstract | Full Article | PDF Published: 23 Feb 2017 / DOI: 10.3332/ecancer.2017.721



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence